Early Edge: Exxon Mobil, Genzyme, Visa Inc., and Zions Bancorporation

The oil major fell short of second-quarter revenue expectations

by Elizabeth Harrow (eharrow@sir-inc.com) 7/29/2010 9:26 AM



Today's column includes a mixed second-quarter report from Exxon Mobil Corporation (XOM), increased M&A speculation for Genzyme Corporation (GENZ), post-earnings price-target cuts for Visa Inc. (V), and a newly struck CDO deal for Zions Bancorporation (ZION). Each day, Early Edge focuses on the hot stocks in the news and gives you a unique insight into each stock's sentiment backdrop. Our time-tested contrarian approach centers on options, and gives you the trading tools to approach the day with a much-needed edge over the investing herd.

Exxon Mobil Corporation

Exxon Mobil Corporation (XOM) took the earnings stage this morning, with the oil major reporting a second-quarter profit of $7.56 billion, or $1.60 per share, up 91% from its year-ago results. Analysts were anticipating a slightly less robust quarterly profit of $1.46 per share. Revenue for the period climbed 24%, but fell short of Wall Street's consensus expectations for $98.49 billion.

XOM price chartOil and gas output increased 8% for the quarter, and results were also boosted by a 30% year-over-year jump in crude oil prices. XOM's downstream business also flourished, with its refining unit raking in a stronger-than-forecast profit of $1.22 billion, compared to its year-ago earnings of $512 million.

XOM has added 0.6% in pre-market trading, but the stock is sitting on a year-to-date deficit of nearly 11%. Today's stronger-than-forecast profits could give the shares a chance to challenge resistance from their 80-day and 200-day moving averages.

Ahead of this morning's report, traders on Wednesday placed their bets on an upside surprise. The equity's August 62.50 call saw 17,938 contracts change hands, with 65% trading at the ask price -- indicating they were purchased. Open interest climbed by 4,410 contracts overnight, confirming that new bullish bets were opened here on Wednesday.

Genzyme Corporation

Speculation is heating up about a potential buyout bid for Genzyme Corporation (GENZ). People familiar with the matter told The Wall Street Journal that Sanofi-Aventis (SNY) is likely to launch a formal bid to Genzyme's board in the next several days, with the proposed bid reportedly valued around $70 to $75 per share. However, Sanofi-Aventis CEO Chris Viehbacher declined to comment on buyout rumors.

GENZ is up nearly 5% ahead of the bell, adding to its 2010 gains of 38.7%. The stock has bolted higher lately in the wake of increased merger-and-acquisition speculation, with the shares lingering near $68 for the past several sessions.

Options players have responded to the rumors by loading up on calls. During the past 10 days, traders on the International Securities Exchange (ISE) bought to open 4.79 calls for every put on GENZ. This ratio ranks higher than 91% of other such readings taken during the past year, marking a near-peak of bullishly biased option buying.

Receive FREE access to Schaeffer’s
Sentiment Spring 2009
premier online options magazine!
Featured Companies






Partner Center

tribal fussion